American Healthcare REIT, Inc.

American Healthcare REIT, Inc. (AHR) Market Cap

American Healthcare REIT, Inc. has a market capitalization of —.

No quote data available.

CEO: Jeffrey T. Hanson

Sector: Real Estate

Industry: REIT - Healthcare Facilities

IPO Date: 2024-02-07

Website: https://www.americanhealthcarereit.com

American Healthcare REIT, Inc. (AHR) - Company Information

Market Cap: -|Sector: Real Estate

Company Profile

American Healthcare REIT (AHR) was forged through a significant strategic consolidation, combining Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, along with integrating the business and operations of American Healthcare Investors. This comprehensive merger has established AHR as a leading global real estate investment trust focused on healthcare properties, boasting an impressive portfolio with a gross investment value of approximately $4.2 billion. A core strength of the company lies in its fully integrated management platform, staffed by over one hundred highly experienced and proficient professionals. Many members of this team have a long history of collaboration, dating back to 2006, and have successfully invested in and overseen healthcare real estate assets across diverse market cycles. Their collective expertise, extensive industry network, and deep, firsthand understanding of each property within the international portfolio – which they have meticulously built and managed since its first acquisition in 2014 – are unparalleled. This powerful combination of a robust management team and a high-quality asset base strategically positions American Healthcare REIT to capitalize on compelling growth opportunities, driven by significant demographic trends. Its expansive portfolio encompasses 19 million square feet across 312 distinct properties, including medical office buildings, senior housing communities, skilled nursing facilities, and integrated senior health campuses. This diverse collection is strategically distributed across 36 U.S. states and the United Kingdom. The aforementioned tri-party transaction represented a pivotal step in ideally preparing American Healthcare REIT for a future public listing or Initial Public Offering (IPO) on a national stock exchange when market conditions are most favorable. By eventually listing its shares, the company anticipates gaining enhanced access to attractive capital sources, which will be crucial for fueling future expansion, diversifying its investor base, and providing greater liquidity for its existing stockholders. American Healthcare REIT, Inc. operates as a subsidiary of Griffin Capital Company, LLC.

Analyst Sentiment

90%
Strong Buy

From 15 Active Polls

1Y Forecast: $60.71

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$56

Median

$60

High Bound

$70

Average

$61

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$60.71
▲ +9.19% Upside
Low Target
$56.00
1% Risk
Median Target
$60.00
8% Mid
High Target
$70.00
26% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

valuation & financial ratiosdetailed financials

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 AMERICAN HEALTHCARE REIT INC (AHR) — Investment Overview

🧩 Business Model Overview

American Healthcare REIT Inc (AHR) invests in income-producing healthcare real estate, typically structured to generate recurring lease income from operating healthcare tenants. The value chain runs from (1) selecting and acquiring regulated, facility-intensive healthcare properties, (2) leasing space to established care providers under longer-dated arrangements (often with contractual protections and/or property-level controls), and (3) maintaining asset quality through property management and capital planning so that facilities remain compliant with healthcare operating requirements and tenant standards. Because care delivery depends on fixed physical infrastructure and local operations, AHR’s tenant base generally faces practical constraints when attempting to relocate, which supports lease stability and cash flow visibility relative to less specialized real estate categories.

💰 Revenue Streams & Monetisation Model

AHR’s monetisation is primarily driven by lease revenue, which is generally recurring in nature and underpinned by the healthcare real estate operating model. Margin drivers are less about pricing power in the consumer sense and more about (1) lease terms (duration, escalators, and contractual rent protection features), (2) property-level operating performance and capital adequacy (to keep facilities rentable under regulated standards), and (3) tenant credit quality. In periods when tenant cash flow is under pressure, the key determinant becomes whether contractual structures and asset coverage support continued rent payments and protect the REIT’s access to external capital.

🧠 Competitive Advantages & Market Positioning

AHR’s core competitive edge is an operational “healthcare real estate specialization” moat rather than a technology or brand moat. Healthcare facilities have high barriers to entry due to licensing, regulatory compliance, construction complexity, and the time required to credential and operationalize a new care site. For operators, relocating is not a simple substitution decision because it involves market re-establishment, staffing, payer contracting dynamics, and regulatory approvals—creating practical switching costs at the facility level. For the REIT, these same characteristics translate into more durable demand for well-positioned, compliant assets and reduce the ease of competitor “churn” into the portfolio’s niches.

  • Intangible / expertise moat: Tenant screening, healthcare-specific underwriting, and asset stewardship designed around regulated operating requirements.
  • Barriers-to-entry moat (healthcare regulation): The difficulty of bringing new healthcare supply online supports the long-run collectability of existing, compliant assets.
  • Tenant/facility stickiness: Operators face high friction in changing facilities, supporting lease continuity and value retention.

COMPETITIVE BENCHMARKING:

  • Omega Healthcare Investors (OHI): A larger-scale skilled nursing focus with broader portfolio diversification across senior care operators.
  • Sabra Health Care REIT (SBRA): Concentration in post-acute/senior housing with a different tenant mix and coverage strategy.
  • Medical Properties Trust (MPW): Greater exposure to hospital and specialty care footprints, with a different regulatory and lease risk profile.

Compared with these peers, AHR’s positioning emphasizes healthcare real estate outcomes tied to facility-level compliance and tenant-operational relationships. The differentiation is less about broad diversification across every care setting and more about building a portfolio where tenant stickiness, underwriting discipline, and asset stewardship are central to performance.

🚀 Multi-Year Growth Drivers

  • Demographic demand for long-term and post-acute care: Aging populations support a structurally higher utilization of skilled and supportive care services, underpinning occupancy needs and replacement demand.
  • Regulated supply dynamics: Building new healthcare facilities involves regulatory scrutiny, long lead times, and operational ramp-up constraints, which can slow supply growth relative to demand.
  • Operational modernization and re-contracting leverage: Facilities that meet evolving care delivery standards can sustain tenant relevance, supporting renewals, extensions, and redevelopment-led value capture.
  • Acquisition opportunity in fragmented markets: Healthcare real estate remains fragmented, creating ongoing deal flow for disciplined buyers who can underwrite tenant credit and property durability.

⚠ Risk Factors to Monitor

  • Tenant credit and lease collectability risk: Healthcare tenants can experience margin pressure from reimbursement dynamics, staffing costs, and utilization changes; stress can lead to lease renegotiations or defaults.
  • Regulatory and reimbursement changes: Shifts in Medicare/Medicaid reimbursement rules, quality metrics, or staffing requirements can affect operator cash flow and, by extension, rent performance.
  • Interest rate and refinancing risk: REIT financing structures can be sensitive to cost of capital, particularly if refinancing is required during periods of tighter credit conditions.
  • Concentration and geographic/event risk: Tenant concentration, operator-specific issues, or local economic/regulatory factors can amplify downside versus diversified portfolios.
  • Capital intensity and compliance capex: Maintaining facilities to current healthcare operating standards can require continuous investment to prevent value erosion and rent impairment.

📊 Valuation & Market View

Healthcare REIT valuation typically hinges on income durability and cash flow quality rather than short-term earnings optics. Market participants often focus on metrics such as P/FFO or EV/EBITDA in combination with dividend sustainability, rent coverage, lease duration, tenant credit profiles, and leverage. Key valuation drivers include (1) the stability of occupancy and collections, (2) the trend in AFFO/FFO-like cash generation, (3) balance-sheet flexibility (liquidity and refinancing runway), and (4) asset-level resilience to reimbursement and regulatory shifts.

🔍 Investment Takeaway

AHR’s long-term thesis rests on specialized healthcare real estate exposure where regulatory and facility-level constraints create meaningful barriers to entry and practical switching costs for operators. The investment case strengthens when tenant credit quality, lease structuring, and asset stewardship align—supporting recurring cash flow generation and resilience amid reimbursement and operational volatility. The main debate centers on underwriting discipline and the ability to preserve rent collectability through cycles in healthcare operator fundamentals.


⚠ AI-generated — informational only. Validate using filings before investing.

Related Companies in Real Estate

COSTAR GROUP INC (CSGP)

Real Estate

$11.65B

Mkt Cap

INVITATION HOMES INC (INVH)

Real Estate

$17.65B

Mkt Cap

VICI PPTYS INC (VICI)

Real Estate

$29.01B

Mkt Cap

CAMDEN PROPERTY TRUST REIT (CPT)

Real Estate

$11.14B

Mkt Cap

SBA COMMUNICATIONS REIT CORP CLASS (SBAC)

Real Estate

$19.20B

Mkt Cap

ALEXANDRIA REAL ESTATE EQUITIES RE (ARE)

Real Estate

$8.97B

Mkt Cap

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"Aehr (“AHR”) reported Q1’26 revenue of $650.8B and net income of $23.7B, with EPS of $0.13 (net margin ~3.64%). On a QoQ basis, revenue rose sharply versus Q4’25 ($650.8B vs $604.1M), and net income increased ($23.7B vs $10.8M). On a YoY basis (Q1’26 vs Q1’25), revenue increased ($650.8B vs $540.6M) and net income turned positive ($23.7B vs -$6.8M); EPS also moved from -$0.0434 to $0.13. Profitability looks volatile across the four quarters, with net margin much lower than the stronger Q3’25 level (Q3 net margin ~9.76%) and higher than Q1’25 (negative). Cash flow was modestly positive in Q1’26: operating cash flow was ~$81.1M and free cash flow ~$81.1M (capex ~0). The balance sheet shows substantial growth in total assets (to ~$5.60T) and liabilities (to ~$2.08T) from Q4’25, while total equity remains sizable (~$3.52T). There were no dividends paid in Q1’26; earlier periods included dividend outflows. Total shareholder returns were strongly positive given the stock’s 1-year change of +63.56%, which meaningfully boosts the score. Analyst consensus targets (~$56.75) remain below the current price ($49.59), implying mixed-to-cautious upside expectations."

Revenue Growth

Positive

Q1’26 revenue jumped vs both prior periods: QoQ revenue ~$650.8B vs $604.1M (massive increase), and YoY ~$650.8B vs $540.6M (massive increase). Trajectory is not stable quarter-to-quarter, but the latest print is a major up move.

Profitability

Fair

Net income improved strongly QoQ and YoY (Q1’26 net income ~$23.7B vs $10.8M in Q4’25 and vs -$6.8M in Q1’25). However, margins appear highly volatile across the year; Q1’26 net margin ~3.64% is below Q3’25 (~9.76%).

Cash Flow Quality

Fair

Q1’26 operating cash flow was ~$81.1M and free cash flow ~$81.1M (capex ~0), which is positive but small relative to the income statement scale. No dividends paid in Q1’26.

Leverage & Balance Sheet

Fair

Large balance sheet expansion in Q1’26: total assets rose to ~$5.60T and total liabilities to ~$2.08T from much lower levels in Q4’25, while equity remains sizable (~$3.52T). Leverage direction is unclear due to substantial changes in reported line items.

Shareholder Returns

Good

Strong momentum with 1-year price change of +63.56% materially increases total return potential. Dividend yield is low (~0.53%) and buyback activity in Q1’26 appears limited.

Analyst Sentiment & Valuation

Neutral

Consensus target (~$56.75) is modest versus current ~$49.59 (mixed upside). No clear valuation edge is indicated from the provided target range.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

RevenueEarningsP/E RatioSharesDebtMargin %

Fundamentals Overview

Loading fundamentals overview...

AHR reported Q1 2026 execution consistent with a long-run operator-centric model: total portfolio same-store NOI grew 12.1% for the ninth straight quarter, supported by sharp occupancy improvements and expanding margins in both Trilogy (ISHC) and SHOP. ISHC occupancy averaged 91.2% (+~220 bps YoY) and NOI margins crossed 20% for the first time since COVID, while SHOP occupancy averaged 88.6% (+~255 bps) and NOI margin expanded ~215 bps to 20.6%. Financially, Q1 normalized FFO/NFFO was $0.50/sh (+31.6% YoY), enabling a full-year raise: same-store NOI guidance to 9%–12% (Trilogy 11%–15%, SHOP 15%–19%) and NFFO/sh to $2.03–$2.09 (midpoint +$0.04; ~20% growth vs 2025). Balance sheet leverage improved to 3.0x net debt/EBITDA, supported by $412.7m ATM forward proceeds and an increased $800m revolver with zero drawn. Key watch items in Q&A were SHOP pacing/seasonality and Trilogy margin drivers tied to Medicare Advantage inflation sensitivity.

AI IconGrowth Catalysts

  • Total portfolio same-store NOI growth of 12.1% (9th consecutive quarter of double-digit growth)
  • Trilogy (ISHC) same-store NOI growth of 14.5% with occupancy averaging 91.2% (+~220 bps YoY) and rate/quality mix improving (quality mix 75.5% of resident days; +~60 bps YoY on same-store; +200 bps total portfolio)
  • Trilogy same-store NOI margins eclipsed 20% for the first time since COVID
  • SHOP same-store NOI increased 19.7%; occupancy averaging 88.6% (+~255 bps YoY) and NOI margin expanded ~215 bps to 20.6%
  • Hands-on asset management and real-time, unit/acuity-level pricing levers to sustain above-historic NOI growth through 2026

Business Development

  • Closed 5 previously announced SHOP communities in California and Missouri for ~$117.5 million
  • Closed 2 additional SHOP properties in Kansas for ~$45.3 million
  • Subsequent to quarter end: closed 6 more SHOP assets in Georgia and South Carolina for ~$86.4 million (deepening Southeast presence)
  • Named operating partners cited: Trilogy Management Services; Senior Solutions Management Group; Great Lakes Management; Compass Senior Living; Heritage Senior Living; Cogir Senior Living; Priority Life Care; Heritage Communities; WellQuest Living

AI IconFinancial Highlights

  • Normalized FFO / NFFO (normalized funds from operations) for Q1 2026: $0.50 per diluted share vs $0.38 in Q1 2025 (+31.6%)
  • Same-store NOI guidance raise / full-year 2026 outlook: total portfolio same-store NOI growth raised to 9% to 12%; midpoint implies double-digit total portfolio same-store NOI growth for third consecutive year
  • Segment guidance (full year 2026): Trilogy 11% to 15%; SHOP 15% to 19%; outpatient medical 0% to 2%; triple-net lease 2% to 3%
  • Balance sheet leverage improved: net debt to annualized EBITDA 3.0x as of March 31, 2026 vs 3.4x at end of 2025
  • NFFO per share guidance increased to $2.03 to $2.09 (midpoint +$0.04), implying ~20% NFFO per share growth vs 2025
  • Explicit margin/occupancy bps: ISHC occupancy +~220 bps YoY; quality mix +~60 bps YoY (same-store) / +200 bps (total portfolio); SHOP occupancy +~255 bps YoY; SHOP NOI margin +~215 bps to 20.6%

AI IconCapital Funding

  • ATM forward sale agreements: entered in Q1 and early Q2 to sell ~8.1 million shares for $412.7 million gross proceeds
  • Unsettled forward agreements under ATM as of call date: ~$527.4 million gross proceeds (assuming full physical settlement)
  • Additional ATM capacity: 'well over $1 billion' available on existing program; continued opportunistic use depending on stock trading
  • Credit facility amendment post quarter-end: unsecured revolver increased from $600 million to $800 million; maturity extended to April 2030 with two 6-month extension options; revolver utilization 0 outstanding
  • Dividend/distribution framing: board allows retaining 'a not inconsequential amount' of retained earnings to fund capital needs given REIT payout requirements

AI IconStrategy & Ops

  • Operator-first underwriting: underwriting the operator first, then asset; leverages off-market/limited-process informational advantage
  • Acquisition pace and pipeline: closed $249.2 million year-to-date (all SHOP); $162.8 million in Q1; additional ~$86.4 million closed post quarter end
  • Awarded-but-not-closed pipeline: over $650 million awarded deals expected to close well before end of 2026 (almost exclusively in SHOP)
  • Development / in-process pipeline: ~$173.9 million expected cost with ~$52.4 million funded to date; predominantly Trilogy campus expansions and independent living villa projects; positioned as capital-efficient growth with limited market risk
  • SHOP pricing approach: measured, resident-focused in-place pricing while managing street rates; dynamic revenue/expense management market-by-market, asset-by-asset, unit-by-unit

AI IconMarket Outlook

  • Full-year 2026 same-store NOI growth guidance range: 9% to 12% (segment ranges: Trilogy 11% to 15%; SHOP 15% to 19%; outpatient medical 0% to 2%; triple-net lease 2% to 3%)
  • Full-year 2026 NFFO per share guidance increased to $2.03 to $2.09 (midpoint implies ~20% growth vs 2025)
  • Pipeline closing expectation: awarded deals (>$650 million) expected to close well before end of 2026

AI IconRisks & Headwinds

  • Medicare Advantage / margin dynamics: Gabe noted Trilogy margin expansion may be 'easier' in 2026, but Medicare growth rate decelerates as it is 'triggered off of inflation' (inflation down implies lower growth rate)
  • Seasonality risk referenced explicitly for SHOP: focus on building occupancy foundation to combat 'regular seasonality pressures' in high acuity portfolio as move-in demand accelerates in spring/summer
  • Competitive intensity: Stefan acknowledged higher deal activity and 'more players entering the senior living space' (risk to pricing discipline / deal availability)
  • Yield / supply dynamics: management emphasized 'stabilized yields in the 7s' contingent on continued disciplined underwriting; supply runway management includes avoiding overbuilt markets like Florida

Q&A: Analyst Interest

  • Topic: SHOP vs Trilogy guidance raise/pacing and whether conservatism is baked in: Management said Trilogy’s strength made raising guidance a “no-brainer” versus a flat rest-of-year profile, while SHOP remained unchanged due to strong conviction and only a first-quarter datapoint. They referenced sequential Q1’25→Q2’25 NOI uptick (~+9.3%) as part of the pause.
  • Topic: Capital sourcing strategy for external growth (pipeline size) and how leverage/ATM fit together: Management explained REIT distribution constraints and emphasized retaining earnings as cheapest equity, then using dispositions of smaller lower-growth assets. They reiterated optionality on ATM forward sales “based on stock price,” credit support for “dry powder,” and commitment to investment-grade-like ratios.
  • Topic: Trilogy profitability outlook—what drives incremental margin/occupancy upside and medium-term constraints: Management linked ongoing occupancy growth to market reputation and Medicare Advantage partner selection, plus proprietary dynamic pricing. They cited last year’s 134 bps margin expansion as a benchmark, said 2026 could get easier with higher occupancy/rate management, but noted Medicare growth decelerates with inflation.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the AHR Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — American Healthcare REIT, Inc. (AHR) Financial Profile